fda ruling on compounded tirzepatide Allows During Shortage Review Compounded GLP-1 Safety: FDA Rules

Onglyza (saxagliptin): US prescribing information

For example, it is possible that the convenience of a once-weekly medication, in contrast to a basal-bolus insulin regimen, which is intensive and requires regular blood glucose monitoring and multiple injections, may have contributed to the relative improvement in HRQoL

Enter retatrutide (LY3437943), a novel triple hormone receptor agonist developed by Eli Lilly, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors

In general, dose increases are typically spaced at least 4 weeks apart to help assess tolerability